<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01388582</url>
  </required_header>
  <id_info>
    <org_study_id>06/2011/PC</org_study_id>
    <nct_id>NCT01388582</nct_id>
  </id_info>
  <brief_title>The Effect of Hormonal Contraceptives on Breast-milk Production and Infant Growth</brief_title>
  <official_title>The Effect of 30mcg and Levonorgestrel 150 Combined Oral Contraceptive, Etonogestrel-releasing Subdermal Implant and Levonorgestrel-releasing Intrauterine System on Breast-Milk Production and Infant Growth in Fully Breast-Feeding Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a randomized clinical trial comparing the effect of 30 mcg ethinyl
      estradiol and LNG 150 combination oral contraceptive pills versus placebo, or LNG-IUS or
      Etonogestrel-releasing contraceptive implant (Implanon)on breast-milk intake and infant
      growth in exclusively breastfeeding mother-infant pairs. Mother-infant pairs will be randomly
      assigned either 30 microgram ethinyl estradiol combination oral contraceptive pills or
      identical placebo to start on post-partum day number 42 or Implanon implants or a LNG-IUS.
      All women will be offered nonhormonal contraceptives prior to randomization. The pairs will
      then be followed for four weeks. During this follow-up period, breast-milk intake will be
      quantified by administering deuterium oxide to exclusively breast-feeding mothers and
      measuring the enrichment of deuterium oxide in the saliva of their infants, otherwise known
      as the dose-to-mother method of Coward.17 Additionally, maternal and infant anthropometric
      measurements will be collected -- both as a value necessary to implement the breast-milk
      quantification method, as well as an outcome for analysis, and a daily diary will be kept by
      the women participating in the study that records infant feeds and diaper changes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women where allocated to an oral combined contraceptive pill, or placebo or a LNG-IUS or a
      etonogestrel-releasing subdermal contraceptive implant at day 42 after delivery. After the
      provision of the contraceptive method a 0.5 mg/kg of deuterium 99.99% according to the weight
      of the mother will be administer to all women. One sample of saliva from the mother and the
      child will be collected every day until 21 days after enrollment. Additionally, weight,
      height and size of the leg of each child will be measured at baseline, at the day 11 and at
      the day 21 after enrollment. Also, a diary with information of change of diapers and number
      of breastfeeding will be kept by each mother.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of infant weight, height and size of the tibial</measure>
    <time_frame>women and children will be evaluated at time frame from day 42 through day 64 post-partum</time_frame>
    <description>The study have the purpose to evaluate the infant weight, height and size of the tibial in infant who breastfeeding on demand exclusively and their mother were either users of a combined oral contraceptive, placebo, etonogestrel-releasing subdermal contraceptive implant or levonorgestrel-releasing intrauterine system. Additionally, pregnancy effectiveness and any adversse event will record in all groups of women.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Underweight</condition>
  <arm_group>
    <arm_group_label>Combined oral contraceptive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 women will receive COC during breastfeeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel intrauterine system</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 women will receive a LNG-IUS during breastfeeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Implanon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 women will receive Implanon during breastfeeding</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCu380A intrauterine device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 women will receive a TCu380A intrauterine device as non hormonal contraceptive during breastfeeding</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LNG-IUS</intervention_name>
    <description>10 women will receive the LNG-IUS during breastfeeding</description>
    <arm_group_label>Levonorgestrel intrauterine system</arm_group_label>
    <other_name>Mirena, Bayer, Brazil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implanon</intervention_name>
    <description>60 mcg/day contraceptive implant</description>
    <arm_group_label>Implanon</arm_group_label>
    <other_name>Implanon, MSD, Brazil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30 mcg EE and 150 LNG oral contraceptive (Microvlar)</intervention_name>
    <description>10 women will receive oral contraceptive during breastfeeding</description>
    <arm_group_label>Combined oral contraceptive</arm_group_label>
    <other_name>Microvlar (Bayer, Brazil)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TCu380A copper-intrauterine device</intervention_name>
    <description>Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group</description>
    <arm_group_label>TCu380A intrauterine device</arm_group_label>
    <other_name>Optima IUD (Injeflex, Brazil)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TCu380A intrauterine device</intervention_name>
    <description>10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding</description>
    <arm_group_label>Combined oral contraceptive</arm_group_label>
    <arm_group_label>Levonorgestrel intrauterine system</arm_group_label>
    <arm_group_label>Implanon</arm_group_label>
    <arm_group_label>TCu380A intrauterine device</arm_group_label>
    <other_name>Implanon, MSD, Os, The Netherland</other_name>
    <other_name>Mirena, Bayer Oy, Tuku, Finland</other_name>
    <other_name>TCu380A copper intrauterine device; Optima, Injeflex, Brazil</other_name>
    <other_name>Microvlar oral contraceptive, Bayer, São Paulo, Brazil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women at the day 42th of post-partum fully breastfeeding-

        Exclusion Criteria:

          -  baby premature

          -  diabetes

          -  blood hypertension

          -  not breastfeeding or partial breastfeeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Bahamondes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Campinas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13083-888</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>July 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2011</study_first_posted>
  <last_update_submitted>May 16, 2012</last_update_submitted>
  <last_update_submitted_qc>May 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Luis Bahamondes</investigator_full_name>
    <investigator_title>MD Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>contraceptives</keyword>
  <keyword>hormonal</keyword>
  <keyword>breastfeeding</keyword>
  <keyword>infant weight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thinness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Copper</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

